GemPharmatech Co., Ltd. (SHA:688046)

Market Cap	6.98B +30.8%
Revenue (ttm)	793.25M +15.5%
Net Income	144.40M +31.5%
EPS	0.35 +29.6%
Shares Out	410.00M
PE Ratio	48.63
Forward PE	45.59
Dividend	0.14 (0.82%)
Ex-Dividend Date	Nov 20, 2025

Volume	2,831,730
Average Volume	3,678,637
Open	17.59
Previous Close	17.59
Day's Range	17.41 - 17.93
52-Week Range	10.44 - 20.50
Beta	0.63
RSI	43.64
Earnings Date	Apr 23, 2026

About GemPharmatech

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other se...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,578
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688046

Financial Performance

In 2025, GemPharmatech's revenue was 793.25 million, an increase of 15.49% compared to the previous year's 686.84 million. Earnings were 144.40 million, an increase of 31.49%.